Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.

ABSTRACT:

Background

Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).

Methods

A cohort was created using data from the EUSTAR database and Nijmegen Systemic Sclerosis cohort, including adult patients who started their first immunosuppressive treatment (i.e. mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab or rituximab) after SSc diagnosis, and no signs of ILD on high-resolution CT. ILD-free survival and the course of forced vital capacity (FVC) % predicted were assessed for up to 5 years' follow-up comparing patients who started early (disease duration ≤3 years) vs l

SUBMITTER: Velauthapillai A 

PROVIDER: S-EPMC12695046 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature